Wall Street Journal Interview: Hepatitis C Drugs are Cost Effective, but Affordability is Another Matter
An interview with the Wall Street Journal on research on the cost-effectiveness and budget-impact of hepatitis C treatment with new antiviral therapies. The study was published in Annals of Internal Medicine.